doi: 10.1111/bph.15208. Epub 2020 Aug 13.
- PMID: 33289534
- DOI: 10.1111/bph.15208
Abstract
A significant number of cannabinoids are known to have analgesic and anti-inflammatory properties in various diseases. Due to their presynaptic/terminal location, cannabinoid receptors can inhibit synaptic transmission and have the potential to regulate neurogenic inflammation. Neurogenic inflammation occurs when a noxious signal is detected in the periphery initiating an antidromic axon reflex in the same sensory neurone leading to depolarization of the afferent terminal. Neuropeptides are subsequently released and contribute to vasodilation, plasma extravasation and modulation of immune cells. Endocannabinoids, synthetic cannabinoids and phytocannabinoids can reduce neuroinflammation by inhibiting afferent firing and inflammatory neuropeptide release. Thus, in addition to a direct effect on vascular smooth muscle and inflammatory cells, cannabinoids can reduce inflammation by silencing small diameter neurones. This review examines the neuropharmacological processes involved in regulating antidromic depolarization of afferent nerve terminals by cannabinoids and the control of neurogenic inflammation in different diseases.
Keywords: Cannabis, arthritis, asthma, inflammation, migraine, pain
© 2020 The British Pharmacological Society.
References
REFERENCES
-
- Ahluwalia, J., Urban, L., Bevan, S., & Nagy, I. (2003). Anandamide regulates neuropeptide release from capsaicin‐sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro. European Journal of Neuroscience, 17(12), 2611–2618. https://doi.org/10.1046/j.1460-9568.2003.02703.x
-
- Ahmed, M., Srinivasan, G. R., Theodorsson, E., Schultzberg, M., & Kreicbergs, A. (1995). Effects of surgical denervation on substance P and calcitonin gene‐related peptide in adjuvant arthritis. Peptides, 16(4), 569–579. https://doi.org/10.1016/0196-9781(95)00025-F
-
- Akerman, S. (2004). Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular‐mediated nociception. Journal of Pharmacology and Experimental Therapeutics, 309(1), 56–63.
-
- Akerman, S., Holland, P. R., & Goadsby, P. J. (2007). Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons. Journal of Pharmacology and Experimental Therapeutics, 320(1), 64–71.
-
- Akopian, A., Ruparel, N., Jeske, N., Patwardhan, A., & Hargreaves, K. (2008). Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia. Trends in Pharmacological Sciences, 30(2), 79–84.
Publication types
